Related Experiment Video
Updated: Jan 30, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Biomarkers of fungal lung infection
José-Artur Paiva1,2,3, José M Pereira1,2,3
1Intensive Care Medicine Department, Centro Hospitalar São João.
Purpose Of Review:
The incidence of lung fungal infections, namely invasive pulmonary aspergillosis (IPA) and mucormycosis, is increasing in neutropenic and nonneutropenic patients. As they are a major cause of death, early diagnosis and antifungal therapy are crucial for outcome. The role of biomarkers in the management of this infections is the scope of this review.
Recent Findings:
Galactomannan in bronchoalveolar lavage shows the best discriminatory power for IPA diagnosis. At baseline, serum galactomannan may be useful to predict outcome and its kinetics may be informative to assess response to antifungal therapy. Recent standardization of PCR technology brought some improvements in IPA and mucormycosis diagnosis. Several new biomarkers are currently under investigation, but none showed a better performance than current available biomarkers. To improve diagnostic accuracy, a combination of biomarkers, including galactomannan, has been proposed.
Summary:
Biomarkers may play an important role in the early diagnosis of fungal lung infections and in prognostic assessment and response monitoring, but more research is needed to determine the best strategy for their clinical use.
Insights
Early diagnosis of invasive pulmonary aspergillosis (IPA) and mucormycosis is critical. Biomarkers like galactomannan show promise for diagnosing and monitoring these severe fungal lung infections.
Area of Science:
- Mycology
- Infectious Diseases
- Pulmonology
Background:
- Invasive pulmonary aspergillosis (IPA) and mucormycosis incidence is rising in both neutropenic and nonneutropenic patients.
- These fungal infections are significant causes of mortality, necessitating prompt diagnosis and treatment.
- Effective management hinges on early detection and appropriate antifungal therapy.
Purpose of the Study:
- To review the role of biomarkers in managing invasive fungal lung infections.
- To assess current and emerging biomarkers for diagnosing and monitoring IPA and mucormycosis.
- To highlight the importance of biomarkers in improving patient outcomes.
Main Methods:
- Review of current literature on fungal lung infection biomarkers.
- Analysis of diagnostic performance of galactomannan and PCR-based methods.
- Evaluation of novel biomarkers under investigation.
Main Results:
- Galactomannan in bronchoalveolar lavage offers the highest diagnostic accuracy for IPA.
- Serum galactomannan can predict patient outcomes and monitor treatment response.
- Standardized PCR techniques have improved IPA and mucormycosis diagnosis, though new biomarkers have not surpassed existing ones.
Conclusions:
- Biomarkers are crucial for early diagnosis, prognosis, and response monitoring of fungal lung infections.
- Combining biomarkers, including galactomannan, may enhance diagnostic accuracy.
- Further research is required to optimize biomarker strategies for clinical application.
More Related Videos
Related Concept Videos
Fungal Group Zygomycota
Lung Capacity
Fungal Phylum Microsporidia
Fungal Phylum Ascomycota
Fungal Phylum Basidiomycota
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

